RevMate

RevMate®

A procedure for the proper managements of Lenalidomide and Pomalidomide

Guide Book for RevMate®

Introduction

Lenalidomide and Pomalidomide are drugs similar to thalidomide, which causes teratogenicity in humans. Teratogenicity is reported in studies on pregnant cynomolgus monkeys for Lenalidomide and on pregnant rabbits and rats for Pomalidomide. Therefore, we have established "RevMate®" a procedure for the proper managements of drugs that should be followed with the aim of preventing exposure to the unborn babies (fetuses). This booklet describes "RevMate®".

*Teratogenicity: Effects that cause serious disability to an unborn baby (fetus)

Information on videos explaining RevMate®

For patients, their families, and those who care for them, the following videos explaining the RevMate® are available on the RevMate® home page.

Background on the creation of RevMate®



Guide to RevMate®



Video

https://www.revmate-japan.jp/patient/movie/

Materials

Materials for patients and their families are available on the RevMate® home page (https://www.revmate-japan.jp/patient/compliance/materials.html).

Contents

1 What is RevMate® ? ····· 4

2 Registration category ····· 7

3 Management procedures ····· 10

4 Male A Pregnancy prevention and proper management ··· 12


5 Female B Requests for prevention and proper management ··· 16

6 Female C Requests for pregnancy prevention and proper drug management ····· 20

7 What you should inform health care providers ····· 26

1 What is RevMate® ?

RevMate® is a procedure to avoid potential serious risks that affect unborn babies (fetuses) caused by Lenalidomide or Pomalidomide and to use the drugs appropriately.
All patients taking Lenalidomide or Pomalidomide and their family members, health care providers such as physicians, pharmacists and nurses, and caregivers, should observe "RevMate®" a proper management procedure.



- **All patients** who will take Lenalidomide or Pomalidomide must **register for the RevMate® program** with a full understanding of RevMate®. Patient's family member(s) and others also should register for the program as a **"Medication care partner"** to manage the drugs; however, a medication care partner may not be required at the discretion of the Prescribing physician (Doctor who prescribes Lenalidomide and Pomalidomide). See P. 8 for the details of Medication care partner.
- Patients will be divided into three registration categories: **Male A** **Female B** **Female C** **according to sex and childbearing potential**.
- "Female patients with childbearing potential" and "male patients" should observe pregnancy prevention procedures, and their contraceptive methods will be confirmed regularly.

Any personal information provided upon registration will only be used for the RevMate® and post-marketing surveillance but not for any other purposes, and will be strictly managed.

For those who are completing the Informed Consent Form for Treatment with Lenalidomide/Pomalidomide

- Your RevMate® registration information will be provided to the RevMate® Center operated by Bristol-Myers Squibb Company (BMS) by the Prescribing physician and will be registered with RevMate®, which is operated and maintained by the RevMate® Center.
- If you take a drugs that is manufactured and sold by a company other than BMS, your RevMate® registration information will be provided by the RevMate® Center operated by BMS to the manufacturer of the drugs you are taking.

For those taking a different Lenalidomide/Pomalidomide product other than the Lenalidomide/Pomalidomide product they are currently taking

- If you intend to take Lenalidomide and Pomalidomide product from a different manufacturer than the Lenalidomide and Pomalidomide product you are currently taking, the RevMate® registration information will be provided to the manufacturer from which you will take the Lenalidomide and Pomalidomide product.

RevMate® registration information refers to the following information.

- Date of application ・Date of registration ・RevMate® Patient ID
- Date of birth ・Name of registered physician
- Patient classification (Male A, Female B, Female C)
- Disease category (disease name: MM / MDS(5q-) / ATLL / FL / MZL / others)
- Prescription date ・Prescribed drugs ・Prescribing physician ・Prescription status
- Confirmation of prescribing requirements ・Specification ・Daily dose ・Prescription days
- Quantity prescribed ・Quantity of remaining drugs ・Date of return
- drugs to be returned ・Quantity of drugs to be returned
- Existence or non-existence of consent form
- Whether or not submitting periodic "RevMate® Patient Survey Sheet" (except for Female B)
- Date and details of change in patient registration information
- Necessity of a Medication care partner
- Pregnancy test date and result (Only female C)
- Next scheduled pregnancy test date (Only female C)
- Last menstrual period start date (Only female C)

RevMate® registration information will be used to manage the safe and proper prescribing, administration, and disposal of Lenalidomide and Pomalidomide.

Why is the RevMate® program necessary?

- Lenalidomide and Pomalidomide are drugs closely resemble thalidomide, which can cause teratogenicity* in humans. Teratogenicity have been reported in studies of Lenalidomide Studies in pregnant cynomolgus monkeys, and for Pomalidomide studies in pregnant rabbits and rats,
- Therefore, also overseas, Lenalidomide and Pomalidomide are used under the program to avoid potential risks affect on unborn babies (fetuses).

*Teratogenicity: Adverse drug reactions leading to serious defects unborn babies (fetuses)

It is necessary to comply with RevMate® program to avoid risks on unborn babies (fetuses) caused by teratogenic Lenalidomide and Pomalidomide.

■Risks of the drug affecting an embryo and fetus

- Thalidomide carries the highest risk of drug-induced teratogenicity during 3-8 weeks of the early pregnancy period.
- Since pregnancy is difficult to recognize during this period, when taking Lenalidomide and Pomalidomide, not only patients but also family members and caregivers should be well aware of a risk of teratogenicity and pay attention to it.

2 Registration category

In RevMate®, patients are divided into one of three groups:

Male A **Female B** **Female C**

Male

Female

Is any of the following applicable?

(1) Have had natural menopause (45 years old or older and with no menses for at least one year), have undergone hysterectomy or bilateral oophorectomy, or have congenital absence of the uterus or bilateral ovaries.

(2) Regardless of age, a lack of ovarian function confirmed periodically by an obstetrician/gynecologist in accordance with the Guidelines for Office Gynecology in Japan(Section on "Premature Ovarian Failure" in Chapter of "Gynecology Outpatient").

(3) The prescribing physician has determined there to be no opportunity for the patient to become pregnant for reasons of a serious physical problem such as poor general condition, on the basis of the patient's report.

Applicable **Not applicable**



Male A



Female B



Female C

(female patients of childbearing potential)

In case of changing registration category

If the registration category is changed during treatment, patients must receive an explanation on the new category and submit the informed consent.

Establishment of a Medication Care Partner


To prevent accidental ingestion of Lenalidomide and Pomalidomide by non-patients and to ensure the return of unneeded drugs, a "Medication care partner" who is in charge of managing drugs on behalf of patients, is appointed in principle.
The prescribing physician will certify those whom the prescribing physician determines meet all of the following requirements from "human beings close to the patient (family members, relatives, neighbors)", "health care providers", "nursing staff", and others.

- Understanding that Lenalidomide and Pomalidomide may cause defects in the fetus.
- Understanding that the prescribed Lenalidomide and Pomalidomide should not be shared or given away to anyone other than the patient.
- Having regular contact with the patient.

After understanding the contents of each section of the "Informed Consent Form for Procedures for Appropriate Control of Lenalidomide and Pomalidomide (Medication Care partner)", please sign the form.

Issue of the RevMate® Card

(1) Receive the "RevMate® Patient Registration Application Form" from Prescribing physician and submit it to the Pharmaceutical Department (hospital pharmacy).
(2) Register yourself with RevMate® at the Pharmaceutical Department (hospital pharmacy).
(3) Your RevMate® Card is issued.



Be sure to bring your RevMate® Card whenever you visit your physician.

Precautions

- The type or number of capsules taken as a dose may be changed during the course of the treatment. Take the medication in accordance with the prescribing physician's directions.
- If unused capsules remain due to treatment discontinuation or change of administration, return them to the Pharmaceutical Department (hospital pharmacy). No refund is available for the returned drug.

For more information on drugs that require RevMate® compliance, please visit the RevMate® website (https://www.revmate-japan.jp/).

3 Management procedures

Before the initial Lenalidomide/Pomalidomide treatment, patients must understand and consent to the treatment.

Steps to receiving the drug for the initial administration



Male A



Female B



Female C

Pregnancy test and confirmation of compliance with contraceptive methods.
(4 weeks prior to medication start*1 and at treatment initiation*2)

(1) Receive an explanation of RevMate® program and compliance from your physician.

(2) Understand RevMate® program and compliance and give consent to Lenalidomide and Pomalidomide treatment.

(3) Submit a set of the required documents to the Pharmaceutical Department (hospital pharmacy).

(4) Receive an explanation of compliance with RevMate® program again from a pharmacist.

(5) Receive the drug and your RevMate® Card.

*1 If sexual intercourse has been abstained from 4 weeks or more before the scheduled treatment initiation, it can be skipped.
*2 From 3 days before till immediately prior to treatment initiation.

When you receive the drug for the second and subsequent times, the remaining capsules are counted.
If you receive the periodic "RevMate® Patient Survey Sheet", complete and submit it to a pharmacist or Prescribing physician at your next visit.

Steps to receive the drug for the second and subsequent times



Male A



Female B



Female C

Pregnancy test and confirmation of compliance with contraceptive methods.

(1) Receive an explanation of RevMate® program and compliance from Prescribing physician.


(2) Inform if the registration category has changed.
e.g. from Female B to Female C

(3) Report the type of drugs previously prescribed and the number of remaining drugs.

(4) Submit a set of the required documents to the Pharmaceutical Department (hospital pharmacy).

(5) Receive an explanation of compliance with RevMate® program again from a pharmacist.

(6) Receive the drug.
If you receive the periodic "RevMate® Patient Survey Sheet", complete and submit the sheet to the pharmacist or Prescribing physician at the next visit.



●For Female B and during hospitalization, filling out the periodic "RevMate® Patient Survey Sheet" is not required.

Male A :

4 Pregnancy prevention and proper management

Pregnancy prevention



Treatment with Lenalidomide/ Pomalidomide may cause serious effects on the baby (fetus)on your partner.

Drug exposure to pregnant women and babies (fetuses) must be avoided.

The drug will be excreted in semen.
From treatment initiation through to 4 weeks after treatment discontinuation (including treatment suspension period), following items must be followed.

- Abstain from sexual intercourse.
- If you have sexual intercourse, be sure to use a condom. Using contraceptive methods* for your partner is recommended.
- Never have any sexual intercourse with a pregnant woman.
- Never donate sperm or semen.


*For details of contraceptive methods see Section "Contraceptive methods" on page 22.

If your partner becomes pregnant or may be pregnant, consult Prescribing physician immediately.

Proper drug management

- **Take the drug in accordance with the instruction by Prescribing physician.**
- **Store and manage the drug at your home at your own risk.**
  Or, **the medication care partner should manage** the drug.
- Complete the periodic **"RevMate® Patient Survey Sheet" (bimonthly)** and **be sure to submit** it.
- Treatment with the drug may be discontinued if you don't observe RevMate® program.

The periodic "RevMate® Patient Survey Sheet" is to confirm that RevMate® procedures are followed appropriately, such as properly managing drugs at home and avoiding pregnancy.



80003

Pharmacist ⇒ Patient ⇒ Pharmacist ⇒ FAX to RevMate® Center: 0120-021-507 (toll free)
TEL: 0120-071-025 (toll free)

RevMate® Patient Survey Sheet

Male A

Mark inside the box ☐.
To check, insert circle in an appropriate box, like ☒.

This sheet is to confirm compliance with the procedures for RevMate®.

Please confirm your RevMate® patient ID and your birth of date already entered is correct, then, complete the questionnaire, and submit it to prescribing physician or pharmacist.
Your personal information described in this Sheet will only be used for the purpose of the RevMate® program and will be kept strictly confidential.

Questionnaire for men in Male A Category

Please answer the following questions based on what you have actually done **in the last two months.** (You must enter a circle in either box for each of the questions below.)
Please acknowledge that this questionnaire is designed for all patients falling into Male A Category, although some questions may not be applicable to your daily living.

Example	Have you stored and managed the drug appropriately?	Appropriately managed ○	Not appropriately managed ☐

	Questions	Answers	
1	Have you stored and managed the drug appropriately?	Appropriately managed ☐	Not appropriately managed ☐
2	During the last two months, have you avoided sexual intercourse or used the specified contraceptive method? * The same measures are required up to four weeks after treatment discontinuation and during the drug suspension period.	Avoided sexual intercourse or achieved contraception using the designated method ☐	Could not achieve contraception using the designated method ☐
3	Have you given the drug to somebody else or discarded? * If you have returned the remaining capsules to the prescribed in-house pharmacy, note that it does not mean "given" or "discarded."	Have not given or discarded ☐	Have given or discarded ☐
4	Have you lost the drug?	Have not lost ☐	Have lost ☐

Questionnaire completion date | Name of the patient | *

*"Name of the patient" field is processed to be blacked out when faxing.

This is the end of the questionnaire. Thank you for your cooperation.

薬剤師記入欄

RevMate® の患者ID 8100

患者さんの生年月日 大正 昭和 平成 西暦 年 月 日

薬局 ID | 医療機関名

定期確認票交付日 20 年 月 日 | 定期確認票交付番号

担当薬剤師名 | 連絡先 TEL

RevMate® is a registered trademark of Celgene Corporation (an affiliate of Bristol-Myers Squibb), USA.

Form 27A (Ver.2.0)

Precautions for drug storage and management

Never give the drug to another person.



Separate from food or beverage and store the drug out of reach of children.



Pay attention not to lose any of the drug.
If you have lost any of the drug, immediately inform the Pharmaceutical Department (hospital pharmacy).



Precautions during Treatment period

Swallow the capsules whole without opening them.



Never donate your blood from treatment initiation through to 4 weeks after treatment discontinuation (including treatment suspension period)



Also please observe “Pregnancy prevention” on page 12.

Precautions when visiting hospital

Be sure to bring your RevMate® Card whenever you visit your physician.



When you are hospitalized or move to another hospital, or you are admitted to any facility such as a nursing home, you should inform of taking the drug to be specially managed and present your RevMate® Card.



Report name (dose) and the number of missed capsules to Prescribing physician.

- Any left capsules at treatment discontinuation will be collected at the Pharmaceutical Department (hospital pharmacy) with no refund.



Female B :

5 Requests for prevention and proper management

Requests for drug exposure prevention



Treatment with Lenalidomide/ Pomalidomide may cause serious effects on unborn babies (fetuses).

Must store and manage the drug not to be accidentally taken by others.

Requests for proper drug management

- **Take the drug as instructed by Prescribing physician.**
- **Store and manage the drug at your home at your own risk.**
  Or, **the medication care partner should manage** the drug.
- Please be advised from your physician that you should be confirmed of compliance status to the drug management and take explanation on it.
- Treatment with the drug may be discontinued if you don't observe RevMate® program.

For "Female B", it is not necessary to submit the periodic "RevMate® Patient Survey Sheet"

Precautions for changing registration category

Registration category of **Female B** may be changed to **Female C** during treatment. On every visit to your physician, confirm the followings and inform your physician if applicable:

- Ovarian functions have recovered.
- Serious physical reasons, such as poor general condition, have been resolved/recovered and pregnancy may be expected.

Precautions for drug storage and management

Never give the drug to another person.



Separate from food or beverage and store the drug out of reach of children.



Pay attention not to lose any of the drug.
If you have lost any of the drug, immediately inform the Pharmaceutical Department (hospital pharmacy).



Precautions during Treatment period

Swallow the capsules whole without opening them.



Never donate your blood from treatment initiation through to 4 weeks after treatment discontinuation (including treatment suspension period)



Also please confirm “Precautions for changing registration category” on page 17.

Precautions when visiting hospital

Be sure to bring your RevMate® Card whenever you visit your physician.



When you are hospitalized or move to another hospital, or you are admitted to any facility such as a nursing home, you should inform of taking the drug to be specially managed and present your RevMate® Card.



Report name (dose) and the number of missed capsules to Prescribing physician.

- Any left capsules at treatment discontinuation will be collected at the Pharmaceutical Department (hospital pharmacy) with no refund.



Female C :


6 Requests for pregnancy prevention and proper drug management

Requests for pregnancy prevention



Treatment with Lenalidomide/ Pomalidomide may cause serious effects on unborn babies (fetuses).

Drug exposure to pregnant women and babies (fetuses) must be avoided.



The **status of contraception** is confirmed and a **pregnancy test** is performed at four weeks prior to medication start*2, at treatment initiation*3, at less than four weeks intervals during treatment, at treatment discontinuation, and at four weeks after treatment discontinuation.

*2 If the patient has abstained from sexual intercourse since four or more weeks before the scheduled first day of medication start the confirmation of contraception status and the pregnancy test can be omitted.
*3 From three days before till immediately prior to medication start.

Contraception methods cannot prevent pregnancy 100%. The only way to be certain of pregnancy prevention is "to abstain from sexual intercourse".

Confirmation of contraception status

A pregnancy test takes a certain period from pregnancy to become "positive".
This means that even if you are pregnant, the test will show a "negative" result for the certain period. Therefore, confirmation should be required if your contraception has been appropriate.

Sexual intercourse has been avoided

Yes → **Pregnancy has been avoided appropriately.**

No → **Contraceptive methods have been used**

Two of the followings must be used:

1. Have you used any of the following contraceptive methods?
   - Oral contraceptive pill (low-dose pill)
   - Intrauterine contraceptive device (IUD)
   - Bilateral tubal ligation/removal
2. Has your male partner always use a condom?

Yes → **Pregnancy has been avoided appropriately.**

No → **Pregnancy has not been avoided appropriately.**

If you think your contraception may have failed or there is a possibility of your being pregnant, consult Prescribing physician immediately.



Emergency contraception

If you have had sexual intercourse without using contraception, "emergency contraception" is available.
You may either take an emergency contraceptive pill (levonorgestrel tablet) within 72 hours of sexual intercourse, or a medium-dose pill as soon as possible after sexual intercourse. If you need the method above, consult with an obstetrician and gynecologist.

Contraceptive methods

Both men and women should use contraceptive methods.

Female Be sure to use any of the followings after consulting with an obstetrician and gynecologist and understanding their risks.


Take a contraceptive pill	Use a device	Undergo surgery
↓	↓	↓
Oral contraceptive pill (low-dose pill)	**Intrauterine contraceptive device (IUD)**	**Bilateral tubal ligation/removal**
		
The secretion of female hormones is inhibited to stop ovulation by taking medicine.	A device is inserted into the uterus through the vagina to prevent fertilization.	A procedure to close the tubes to prevent the sperm from reaching the ovum for fertilization.

Male Be sure to wear a condom.

Requests for roper drug management

- **Take the drug as instructed by Prescribing physician.**
- **Store and manage the drug at your home at your own risk.**
  Or, **the medication care partner should manage** the drug.
- Complete the periodic **"RevMate® Patient Survey Sheet"** given **once a month** and **be sure to submit** it.
- Treatment with the drug may be discontinued if you don't observe RevMate® program.

The periodic "RevMate® Patient Survey Sheet" is to confirm that RevMate® procedures are followed appropriately, such as properly managing drugs at home and avoiding pregnancy.



80004

Pharmacist ⇒ Patient ⇒ Pharmacist ⇒ FAX to RevMate® Center: 0120-021-507 (toll free)
TEL: 0120-071-025 (toll free)

RevMate® Patient Survey Sheet

Female C

Mark inside the box ☐.
To check, insert circle in an appropriate box, like ☒.

This sheet is to confirm compliance with the procedures for RevMate®.

Please confirm your RevMate® patient ID and your birth of date already entered is correct, then, complete the questionnaire, and submit it to prescribing physician or pharmacist.
Your personal information described in this Sheet will only be used for the purpose of the RevMate® program and will be kept strictly confidential.

Questionnaire for women in Female C Category

Please answer the following questions based on what you have actually done **in the last one month.** (You must enter a circle in either box for each of the questions below.)
Please acknowledge that this questionnaire is designed for all patients falling into Female C Category, although some questions may not be applicable to your daily living.

Example	Have you stored and managed the drug appropriately?	Appropriately managed ○	Not appropriately managed ☐

	Questions	Answers	
1	Have you stored and managed the drug appropriately?	Appropriately managed ☐	Not appropriately managed ☐
2	During the last one month, have you avoided sexual intercourse or practiced the designated contraception method with your partner? * The same measures are required up to four weeks after treatment discontinuation and during the drug suspension period.	Avoided sexual intercourse or achieved contraception using the designated method ☐	Could not achieve contraception using the designated method ☐
3	Have you given the drug to somebody else or discarded? * If you have returned the remaining capsules to the prescribed in-house pharmacy, note that it does not mean "given" or "discarded."	Have not given or discarded ☐	Have given or discarded ☐
4	Have you lost the drug?	Have not lost ☐	Have lost ☐

Questionnaire completion date | Name of the patient

*"Name of the patient" field is processed to be blacked out when faxing.

This is the end of the questionnaire. Thank you for your cooperation.

薬剤師記入欄

RevMate® の患者ID 8100

患者さんの生年月日 大正 昭和 平成 西暦 年 月 日

薬局 ID

医療機関名

定期確認票交付日 20 年 月 日

定期確認票交付番号

担当薬剤師名

連絡先 TEL

RevMate® is a registered trademark of Celgene Corporation (an affiliate of Bristol-Myers Squibb), USA.

Form 2TCIVer.2.0

Precautions for drug storage and management

Never give the drug to another person.



Separate from food or beverage and store the drug out of reach of children.



Pay attention not to lose any of the drug.
If you have lost any of the drug, immediately inform the Pharmaceutical Department (hospital pharmacy).



Precautions during Treatment period

Swallow the capsules whole without opening them.



Never donate your blood from treatment initiation through to 4 weeks after treatment discontinuation (including treatment suspension period)



Also please observe Requests for pregnancy prevention on page 20.

Precautions when visiting hospital

Be sure to bring your RevMate® Card whenever you visit your physician.



When you are hospitalized or move to another hospital, or you are admitted to any facility such as a nursing home, you should inform of taking the drug to be specially managed and present your RevMate® Card.



Report name (dose) and the number of missed capsules to Prescribing physician.

- Any left capsules at treatment discontinuation will be collected at the Pharmaceutical Department (hospital pharmacy) with no refund.



7 What you should inform health care providers

Please provide this information to your caregivers and health care providers/medical personnel when you are hospitalized (transferred) or admitted to a hospital

Dear healthcare professionals,

- Lenalidomide and Pomalidomide are drugs that closely resemble thalidomide which causes teratogenicity in humans. Accordingly, they are drugs that require special drug accountability (compliance to RevMate®).

Request for proper drug storage and strict verification of dispensing, administration, and intake to prevent medication errors

Drug storage

Please store lenalidomide and pomalidomide separately from other medications so that it is easy to recognize that **they are medications that require special drug accountability (compliance to RevMate®).**[*1]

- To prevent drug exposure, capsules must not be opened.
- Unused lenalidomide and pomalidomide should not indiscriminately be discarded. Instead, they should be returned to the pharmacy department (in-hospital pharmacy).[*2]
- In case you lost medications, please report it to the prescribing doctor or a pharmacist in charge.[*2]

*1 Please handle medications in accordance with the rule set forth at each medical institution.
*2 In case the medical institution is not a registered RevMate® facility, please contact RevMate® center.

Dispensing	Please conduct a double-check of the patient's name, drug name, and dose.
Drug administration	Please always verify the patient's identity.
Verification of drug intake	After a patient takes the medication, a drug administration check should be conducted.

For details, please visit the RevMate® website.

Notes

Access to RevMate® Home Page

The RevMate® website has a page for patients. It also contains patient booklets and videos for your viewing pleasure.

RevMate®website

RevMate

https://www.revmate-japan.jp/

作成：ブリストル・マイヤーズ スクイブ株式会社

RevMate® is a registered trademark of Celgene Corporation (an affiliate of Bristol-Myers Squibb), USA.

RMG00752RB
2026年6月作成